Title:
BISPECIFIC POLYPEPTIDE COMPLEX
Document Type and Number:
WIPO Patent Application WO/2023/046093
Kind Code:
A1
Abstract:
The present invention relates to the field of biomedicines. Provided are a bispecific fusion polypeptide and the use thereof. The bispecific fusion polypeptide comprises a first antigen binding portion, the first antigen binding portion can specifically bind to a first conjugate fragment and a second conjugate fragment, and the first conjugate fragment and the second conjugated fragment are a ligand/receptor pair.
Inventors:
LU DI (CN)
HUO YONGTING (CN)
HUO YONGTING (CN)
Application Number:
PCT/CN2022/120973
Publication Date:
March 30, 2023
Filing Date:
September 23, 2022
Export Citation:
Assignee:
GUANGDONG FEIPENG PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61K38/17; C07K16/46; C12N15/63
Foreign References:
| CN112661854A | 2021-04-16 | |||
| US20200283524A1 | 2020-09-10 | |||
| CN110382525A | 2019-10-25 | |||
| CN105189562A | 2015-12-23 | |||
| CN106084062A | 2016-11-09 |
Other References:
MA LINLIN, JUNWEI GAI, PENG QIAO, YANFEI LI, XIAOFEI LI, MIN ZHU, GUANGHUI LI, YAKUN WAN: "A novel bispecific nanobody with PD-L1 TIGIT dual immune checkpoint blockade", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 531, 8 August 2020 (2020-08-08), pages 144 - 151, XP055826617, DOI: 10.1016/j.bbrc.2020.07.072
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: